Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 1/20 | 0.60 |
| ▸ | CDK9 | P50750 | 1/20 | 0.60 |
| ▸ | INSR | P06213 | 3/20 | 0.58 |
| ▸ | IGF1R | P08069 | 3/20 | 0.58 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.58 |
| ▸ | MAP4K1 | Q92918 | 7/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.53 |
| ▸ | PTK2 | Q05397 | 7/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11916362 | 1.00 | CDK7 (0.60) | CDK7CDK9INSRIGF1RALK | |
| SCHEMBL14240767 | 0.88 | CDK7 (0.48) | CDK7CDK9INSRIGF1RALK | |
| SCHEMBL19313060 | 0.88 | CDK7 (0.59) | CDK7CDK9INSRIGF1RALK | |
| SCHEMBL30503695 | 0.88 | CDK7 (0.48) | CDK7CDK9INSRIGF1RALK | |
| SCHEMBL26717249 | 0.88 | INSR (0.72) | CDK7CDK9INSRIGF1RALK | |
| SCHEMBL30173407 | 0.86 | IGF1R (0.49) | CDK7CDK9INSRIGF1RALK | |
| SCHEMBL22246100 | 0.86 | MAP4K1 (0.48) | CDK7CDK9INSRIGF1RALK | |
| SCHEMBL13832181 | 0.86 | IGF1R (0.49) | CDK7CDK9INSRIGF1RALK | |
| SCHEMBL14240702 | 0.86 | CDK7 (0.58) | CDK7CDK9INSRIGF1RALK | |
| SCHEMBL29833319 | 0.86 | CDK7 (0.61) | CDK7CDK9INSRIGF1RALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112239422-B | Bugatinib intermediate, salt thereof, preparation method thereof and preparation method of brigatinib | 河北化工医药职业技术学院 | 2022-07-22 | — | — | CN | claimed |
| CN-120025316-A | Compound for targeted degradation of ALK protein, and preparation method and application thereof | 成都分迪药业有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-119968373-A | Aromatic heterocyclic compound and preparation method thereof | 上海翊石医药科技有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119735613-A | Crystalline forms of 5-chloro-N4- [2- (dimethylphosphoryl) phenyl ] -N2- { 2-methoxy-4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] phenyl } pyrimidine-2, 4-diamine | 武田药品工业株式会社 | 2025-04-01 | — | — | CN | disclosed |
| CN-119143806-B | Dimethyl phosphine oxide substituted aniline pyrimidine derivative targeting EGFR mutation, preparation method and application thereof, and medicine prepared from dimethyl phosphine oxide substituted aniline pyrimidine derivative | 四川大学华西医院 | 2025-03-11 | — | — | CN | disclosed |
| CN-119552192-A | Preparation method of ALK kinase inhibitor | 齐鲁制药有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-119143806-A | Dimethyl phosphine oxide substituted aniline pyrimidine derivative targeting EGFR mutation, preparation method and application thereof, and medicine prepared from dimethyl phosphine oxide substituted aniline pyrimidine derivative | 四川大学华西医院 | 2024-12-17 | — | — | CN | disclosed |
| CN-115697993-B | Pyrimidine compounds as AXL inhibitors | 南京正大天晴制药有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-118976029-A | Pharmaceutical composition for preventing or treating parkinson's disease or nonalcoholic steatohepatitis | 韩国化学研究院 | 2024-11-19 | — | — | CN | disclosed |
| CN-114829344-B | Pyrimidine derivatives and pharmaceutical compositions containing the same | 韩国化学研究院 | 2024-08-13 | — | — | CN | disclosed |
| CN-113302196-B | EGFR inhibitor, composition and application thereof | 贝达药业股份有限公司 | 2023-08-04 | — | — | CN | disclosed |
| CN-113004252-B | Aryl imidazole derivative and application thereof | 江苏先声药业有限公司 | 2023-06-09 | — | — | CN | disclosed |
| WO-2023070114-A2 | REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| CN-115697993-A | Pyrimidines as AXL inhibitors | 南京正大天晴制药有限公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2023278325-A1 | BIFUNCTIONAL COMPOUNDS THAT DEGRADE ALK AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| CN-112771032-B | Pyrimidine pyrazole compounds as fourth generation EGFR inhibitors | 江苏先声药业有限公司 | 2023-01-03 | — | — | CN | disclosed |
| CN-114829344-A | Novel pyrimidine derivative and use thereof | 韩国化学研究院 | 2022-07-29 | — | — | CN | disclosed |
| CN-112239422-B | Bugatinib intermediate, salt thereof, preparation method thereof and preparation method of brigatinib | 河北化工医药职业技术学院 | 2022-07-22 | — | — | CN | disclosed |
| CN-110357889-B | Protein degradation targeting compound, anti-tumor application thereof, intermediate thereof and application of intermediate | 上海科技大学 | 2022-03-15 | — | — | CN | disclosed |
| CN-110467637-B | Bisaminyl chloropyrimidine compound containing phosphine oxide substituted aniline, preparation method and application thereof | 北京赛特明强医药科技有限公司 | 2022-02-18 | — | — | CN | disclosed |